The cytokine response to Bacille Calmette Guerin vaccination in South India

International Journal of Tuberculosis and Lung Disease

Volumn 2, Issue 10, 1998, Pages 836-843

  Das, S D ^a   Narayanan, P R ^a   Kolappan, C ^a   Colston, M J ^b  

^a NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

BCG vaccination; Cell mediated immunity; Cytokine response; Lymphocyte proliferation

Indexed keywords

BCG VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; TUBERCULIN;

ADULT; AGED; ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; INDIA; LYMPHOCYTE PROLIFERATION; MALE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ADULT; BCG VACCINE; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, CELLULAR; INDIA; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; MALE; MYCOBACTERIUM BOVIS; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; TUBERCULIN TEST; TUBERCULOSIS;

EID: 0031705818     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Murray C J, Styblo L K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65 (1): 6.
2. Colditis G A, Brewer T F, Berkey C S, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature: JAMA 1994; 271: 698-702.
3. World Health Organization. Tuberculosis Prevention Trials: Madras. Trial of BCG vaccines in South India for tuberculosis prevention. Bull World Health Organ 1979; 57: 819-827.
4. Hart P D, Sutherland I. BCG and Vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Final report to the Medical Research Council. BMJ 1977; 2: 293-295.
5. Tuberculosis Prevention Trial, Madras. Trial of BCG vaccine in South India for tuberculosis prevention. Ind J Med Res 1980; 72 (Suppl.): 1-74.
6. Karonga Prevention Trial of single BCG, repeated BCG or combined BCG plus killed M. leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348: 17-24.
7. World Health Organization. Standard Tuberculin Test Technical Guide. Geneva; WHO. February 1963.
8. Hart P D, Sutherland I, Thomas J. The immunity conferred by effective BCG and Vole bacillus vaccines, no relation to individual variations induced tuberculin sensitivity and to technical variation in the vaccines. Tubercle 1967; 48: 201-210.
9. Comstock G W. Vaccination against tuberculosis: controlled trials of BCG vaccination by the US public health service. In: International Conference on the application of vaccines against viral, rickettsial and bacterial diseases of man. Scientific Publication No. 226, Washington, DC. Pan American Health Organization, 1971; 378-81.
10. Mossman T R, Coffman R L. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7; 145-173.
11. Romangnani S. Lymphokine production by human T cells in disease states. Ann Rev Immunol 1994; 12: 227-257.
12. Hsieh C S, Macatonia S F, Trippo C S, Wolf S F, Garra A O, Murphy K M. Development of Th1 CD+ T cells through IL12 produced by Listeria-induced macrophages. Science, 1993; 260: 547.
13. Palmer C E, Long M W. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 1966; 94; 553: 568.
14. Das S, Cheng S H, Lowrie D B, et al. The pattern of mycobacterial antigen recognition in sera from Mantoux-negative individuals is essentially unaffected by BCG vaccination in either South India or London. Clin Exp Immunol 1992; 89; 402-406.
15. Tripathy S P. Fifteen year follow up of the Indian BCG Prevention Trial. In: Proceedings of the 26th World Conference of the International Union against Tuberculosis, Singapore 1986: 69- 72.
16. Cheng S H, Walker K B, Lowrie D B, et al. Monocyte antimycobacterial activity before and after M. bovis BCG vaccination in Chingleput, India and London, United Kingdom. Infect Immun 1993; 61; 4501-4503.
17. Kawamura I, Tsukada H, Yoshikawa H, Fugita M, Nomoto K, Mitsuyama M. IFN-γ producing ability as a possible marker for the protective T cells against Mycobacterium bovis BCG in mice. 1992.
18. Ravn P, Boesen H, Pedersen B K, Andersen P. Human T cell responses induced by vaccination with Mycobacterium bovis Bacillus Calmette-Guerin. J Immunol 1997; 158: 1949-1955.
19. Sanchez F O, Rodriguez J I, Agudelo G A, Garcia L F. Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls. Infect Immun 1994; 62: 5673- 5678.
20. Elgahazali G E B, Paulic S, Anderson G, et al. Number of IL-4 and IFN-γ secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation. Eur J Immunol 1993; 23; 2740-2745.
21. Enarson D A, Murray J F. Global epidemiology of tuberculosis. In: Rom W and Garay S, eds. Tuberculosis. 1996: pp 57-75.
22. Smith P G, Moss A R. Epidemiology of tuberculosis. In: Bloom B R, ed. Tuberculosis: pathogenesis, protection and control. Washington, DC; American Society for Microbiology. 1994; pp 47-59.